Keywords: Merck & Co, Vicriviroc, Research, HIV/AIDS

Setback for Merck & Co as vicriviroc disappoints in Ph III

Article | 22 January 2010

Print This

Disappointing results from one of US drug major Merck & Co’s pipeline candidates, vicriviroc, are a setback for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in